Influenza virus subunit vaccine (adjuvant) IND application approved

IND application approved
Recently, Yither biotech (Shanghai) Co., Ltd (Yither Bio) and its parent company Ab&B Bio-Tech Co.,Ltd（Ab&B Bio）jointly applied for a Class I new drug "Influenza Virus Subunit Vaccine (Adjuvant)" IND application, which has been approved by the Drug Evaluation Center (CDE) of the China National Medical Products Administration. The approval of this vaccine marks the completion of the full coverage of the company's subunit influenza vaccine product pipeline for trivalent and quadrivalent influenza virus subunit vaccines, providing the most accurate selection for different age groups and different demand groups.

Source: Government Service Website of the Drug Evaluation Center of the National Medical Products Administration

Regarding influenza virus subunit vaccine (adjuvant)
At present, influenza virus remains one of the important respiratory pathogens threatening human public health. Seasonal influenza outbreaks or occasional cross species transmission and pandemics of influenza virus have significant impacts on human health and socio-economic development. Compared to other age groups, the elderly have a higher infection rate and a greater risk of severe illness and death after contracting the flu, which increases with age. WHO and the Chinese Center for Disease Control and Prevention recommend elderly people as one of the priority groups for influenza vaccination.

The trivalent influenza virus subunit vaccine (adjuvant) approved this time is an adjuvant containing influenza vaccine developed by the company in response to the WHO's recommendation for influenza vaccination, using the company's mature platform technology and new adjuvants, suitable for the elderly population aged 65 and above. Preclinical studies have shown that adjuvanted influenza virus subunit vaccines can significantly increase the body's antibody levels and neutralizing antibody titers, and have significant advantages in enhancing immune response capabilities, providing the optimal choice for the elderly population to cope with influenza.

More news
Recently,Ab&B Bio-Tech Co.,Ltd（Ab&B Bio）was shortlisted for the finals of the "Zhichuang Taizhou" Science and Technology Innovation and Entrepreneurship Competition and won the first prize in the Growth and Entrepreneurship Group! This fully affirms the technological attributes of our company's project!